Anixa Biosciences (ANIX) Fundamental Analysis: Revenue, Earnings & Valuation

4.07 / 10

Netural

Fundamental score is 4.07 (Neutral). Strengths include high accounts receivable turnover, interest coverage and revenue‑MV advantage; weaknesses are low fixed‑asset turnover and high income‑tax ratio. Mixed metrics warrant selective attention.

Analysis Checks(7/10)

Revenue-MV

Value-0.08

Score3/3

Weight44.51%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight2.37%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-2.53%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-2.50%

1M Return-0.65%

PB-ROE

Value5.18

Score0/3

Weight18.30%

1M Return3.80%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-5.69%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-4.69%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.82%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-2.77%

1M Return-0.74%

Asset-MV

Value-0.55

Score2/3

Weight55.83%

1M Return9.91%

Is ANIX undervalued or overvalued?

ANIX scores 4.07/10 on fundamentals and holds a Fair valuation at present. Backed by its -18.46% ROE, 0.00% net margin, -8.42 P/E ratio, 6.27 P/B ratio, and 17.95% earnings growth, these metrics solidify its Netural investment rating.